Association analysis of drug metabolizing enzyme gene polymorphisms in AIDS patients with cutaneous reactions to sulfonamides [4]

Journal of Investigative Dermatology

Volumn 125, Issue 5, 2005, Pages 1080-1082

  Wolkenstein, Pierre ^a,b   Loriot, Marie Anne ^c,d   Flahault, Antoine ^e   Cadilhac, Michel ^e   Caumes, Eric ^e   Eliaszewicz, Muriel ^f   Beaune, Philippe ^c,d   Roujeau, Jean Claude ^a,b   Chosidow, Olivier ^e  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c INSERM   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DRUG METABOLIZING ENZYME; PYRIMETHAMINE SULFADIAZINE; SULFONAMIDE; ANTIINFECTIVE AGENT; CYP2C9 PROTEIN, HUMAN; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DNA POLYMORPHISM; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENZYME ANALYSIS; EXFOLIATIVE DERMATITIS; GENETIC ASSOCIATION; HUMAN; LETTER; MACULOPAPULAR RASH; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURITUS; STEVENS JOHNSON SYNDROME; TOXOPLASMOSIS; URTICARIA; ADULT; DRUG DETOXIFICATION; ENZYMOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; MALE; SKIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-INFECTIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG HYPERSENSITIVITY; FEMALE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; POLYMORPHISM, GENETIC; SKIN; SULFONAMIDES;

EID: 33644813856     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23939.x     Document Type: Letter

References (21)

1. Alfirevic A, Stalford AC, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M: Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 55:158-165, 2003
2. Chevrier I, Stucker I, Houllier AM, Cenee S, Beaune P, Laurent-Puig P, Loriot MA: Myeloperoxidase: New polymorphisms and relation with lung cancer risk. Pharmacogenetics 13:729-739, 2003
3. Cribb AE, Spielberg SP, Griffin GP: N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 23:406-414, 1995
4. Eliaszewicz M, Flahault A, Roujeau JC, et al: Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J Am Acad Dermatol 47:40-46, 2002
5. Gill HJ, Tjia JF, Kitteringham NR, Pirmohamed M, Back DJ, Park BK: The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Pharmacogenetics 9:43-53, 1999
6. Harth V, Donat S, Ko Y, Abel J, Vetter H, Bruning T: NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol 73:528-531, 2000
7. Hu X, Ji X, Srivastava SK, et al: Mechanism of differential catalytic efficiency of two polymorphic forms of human glutathione S-transferase P1-1 in the glutathione conjugation of carcinogenic diol epoxide of chrysene. Arch Biochem Biophys 345:32-38, 1997
8. Hu X, Xia H, Srivastava SK, Pal A, Awasthi YC, Zimniak P, Singh SV: Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and benzo[g]chrysene. Cancer Res 58:5340-5343, 1998
9. Koeplinger KA, Zhao Z, Peterson T, Leone JW, Schwende FS, Heinrikson RL, Tomasselli AG: Activated sulfonamides are cleaved by glutathione-S-transferases. Drug Metab Dispos 27:986-991, 1999
10. London SJ, Lehman TA, Taylor JA: Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 57:5001-5003, 1997
11. Morin S, Loriot MA, Poirier JM, et al: Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol 56:793-797, 2001
12. Nedelcheva KV, Andersen TI, Erikstein B, Geitvik G, Skovlund E, Nesland JM, Borresen-Dale AL: Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: Relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. Pharmacogenetics 8:441-447, 1998
13. O'Neil WM, MacArthur RD, Farrough MJ, et al: Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol 42:613-619, 2002
14. Pirmohamed M, Alfirevic A, Vilar J, Stalford A, Wilkins EG, Sim E, Park BK: Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 10:705-713, 2000
15. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK: The danger hypothesis - potential role in idiosyncratic drug reactions. Toxicology 181-182:55-63, 2002
16. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR: Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429-439, 1996
17. Sundberg K, Seidel A, Mannervik B, Jernstrom B: Detoxication of carcinogenic fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferase P1-1 variants and glutathione. FEBS Lett 438:206-210, 1998
18. Svensson CK: Do arylhydroxylamine metabolites mediate idiosyncratic reactions associated with sulfonamides? Chem Res Toxicol 16:1035-1043, 2003
19. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D: Characterization of a polymorphism in NAD(P)H: Quinone oxidoreductase (DT-diaphorase). Br J Cancer 75:69-75, 1997
20. van der Ven AJ, Koopmans PP, Vree TB, van der Meer JW: Adverse reactions to co-trimoxazole in HIV infection. Lancet 338:431-433, 1991
21. Wolkenstein P, Loriot MA, Aractingi S, Cabelguenne A, Beaune P, Chosidow O: Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS. Pharmacogenetics 10:821-828, 2000